

**North of Tyne
Area Prescribing Committee**

www.northoftyneapc.nhs.uk

**Tuesday 8th January 2013.
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt
Business Park.
The meeting will start at 12:30pm**

AGENDA

1. Apologies for absence
2. Declarations of interest
 - Relevant declarations
3. Appeals against previous decisions
4. Minutes and decision summary from the meeting held on 13/11/12 Email 23/11/12
5. Matters arising/actions from previous meeting
6. Report from the Formulary sub-group
 - Unapproved minutes from meeting held on 18/12/12 Enclosed with agenda
 - Decision summary from meeting held on 18/12/12 Enclosed with agenda
7. Report from the Shared Care Group
 - No meeting
8. Report from the Antimicrobial Chemotherapy Sub-group
 - Antibiotic diagram to support primary care guidelines - chairs approval taken. Enclosed with agenda for information
9. Report from Medicines Management QIPP Sub-group
 - Draft minutes from 14/11/12 Enclosed with agenda
10. Development and updating of local formularies and NICE Compliance Enclosed with agenda
11. North of England Specialised Commissioning Group Decision Enclosed with agenda

- Ivacaftor

12. Documents previously circulated by e-mail

- NETAG Treatment Appraisal: Decision Summary - Bevacizumab (Avastin®) for hereditary haemorrhagic telangiectasia Email 27/11/2012
- NETAG Treatment Appraisal: Decision Summary - Perampanel (Fycompa®) for focal epilepsy Email 27/11/2012
- NECDAG CDF Approval - Abiraterone in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease is failing hormone therapy (chemotherapy naïve) Email 6/12/2012
- NECDAG Gateway Decision – Approval – Arsenic trioxide in relapsed or refractory acute promyelocytic leukaemia Email 6/12/2012
- NECDAG CDF Approval - Bevacizumab (Avastin®) in combination with irinotecan for the treatment of Low Grade Gliomas in paediatric patients Email 6/12/2012
- NECDAG Decision document - Glucarpidase (Varoxase®) For the treatment of toxic plasma methotrexate concentrations (>1 micromole per litre) in patients with delayed methotrexate clearance due to impaired renal function, in the following situations: Email 6/12/2012
 - Delayed elimination of methotrexate
 - Impaired renal function
 - Significant methotrexate toxicity
- NECDAG CDF Approval - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours – confirmation of continued approval beyond NICE TAG 265. Email 6/12/2012
- NECDAG Gateway Decision – Approval –Rituximab chemo induction 1st line NHL Email 6/12/2012
- NECDAG Gateway Decision – Approval –Rituximab for the treatment of patients with hairy Cell Leukaemia (HCL) or Hairy cell Leukaemia variant (HCL-v) who: Email 6/12/2012
 - Relapse early after purine analogue therapy (< 2 years post treatment)
 - Are refractory to purine analogues.
-

13. APC Guidelines and Statements for review

- None

14. NICE Technology Appraisals published November and December:

- TA266: Cystic fibrosis - mannitol dry powder for inhalation – Bronchitol
- TA 267: Chronic Heart Failure - Ivabradine
- TA268: Melanoma (stage III or IV) - ipilimumab

- TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib

15. Chairman's action

- Newer Oral Anticoagulants Comparison Document {Circulated for
- Newer Oral Anticoagulants Licensed Indications {comment 19/11/12

16. Any other business

- Subgroup Terms Of Reference

17. Date and time of next meeting:

Tuesday 12th March 2013

Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park, North Tyneside.

The meeting will start at 12:30pm